

Breast Cancer HER2-Positive Breast Cancer

**A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)**

**Trial Status**  
Completed

**Trial Runs In**  
5 Countries

**Trial Identifier**  
NCT02913456 MO39146

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.

**Hoffmann-La Roche**  
Sponsor

Phase

**NCT02913456 MO39146**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No